These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15359849)

  • 1. [Two-step interferon rebound therapy].
    Kato M; Yuki N; Iyoda K; Yamamoto K; Hayashi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):497-501. PubMed ID: 15359849
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
    [No Abstract]   [Full Text] [Related]  

  • 3. Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment.
    McGowan CE; Dougherty KA; Fried MW
    Liver Int; 2011 Jul; 31(6):903-4. PubMed ID: 21645223
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
    Cuccorese G; Tursi A; Spinazzola AM; Modeo ME; Miglietta A
    Am J Gastroenterol; 2000 Sep; 95(9):2399-400. PubMed ID: 11007262
    [No Abstract]   [Full Text] [Related]  

  • 5. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Henry MJ
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
    [No Abstract]   [Full Text] [Related]  

  • 6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
    Klinker H
    MMW Fortschr Med; 2003 Oct; 145(41):39-40. PubMed ID: 14655480
    [No Abstract]   [Full Text] [Related]  

  • 9. Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels.
    Antonucci G; Angeletti C; Vairo F; Longo MA; Girardi E
    J Infect Dis; 2009 Nov; 200(9):1484-5; author reply 1485. PubMed ID: 19817588
    [No Abstract]   [Full Text] [Related]  

  • 10. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Puoti C; Bellis L; Castellacci R; Montagnese F
    Hepatology; 2005 Mar; 41(3):683; author reply 684. PubMed ID: 15723301
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
    Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
    Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 13. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
    Dusheiko G; Danta M
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
    [No Abstract]   [Full Text] [Related]  

  • 15. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
    Serfaty L; Fartoux L; Poupon R
    J Hepatol; 2009 Jun; 50(6):1269-71. PubMed ID: 19395115
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
    Chu CJ; Lee SD
    J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
    [No Abstract]   [Full Text] [Related]  

  • 20. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
    Pawłowska M; Palewicz E; Halota W
    Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.